Mark Cuban recently shared his thoughts on President Trump’s new online pharmacy, TrumpRx.gov, giving it a preliminary grade of “B”. This government-run initiative aims to let consumers buy prescription drugs directly from manufacturers, bypassing Pharmacy Benefit Managers (PBMs). The expectation is for the website to launch in 2026.
Cuban, a billionaire entrepreneur known for his venture Cost Plus Drugs, believes TrumpRx could benefit patients and even help his own business. He noted that while the program has promise, the stock prices of major PBMs, like CVS and Cigna, did not drop significantly, suggesting that many still believe the system will remain largely unchanged.
He expressed concerns that the initiative might still favor the PBMs, which often negotiate rebates from drug makers. These rebates can lead to higher drug prices, as they are typically tied to a drug’s list price. Critics argue that this setup inflates costs and contributes to soaring insurance premiums. In contrast, Cuban’s Cost Plus Drugs operates on a straightforward model, marking up drugs by 15% above their wholesale price, providing transparency and affordability.
As TrumpRx.gov plans to feature products from Pfizer, including lower-cost options for Medicaid, the response from users and the public could significantly shape its future. Recent data from the Commonwealth Fund indicates that around 80% of the U.S. drug market is controlled by three large PBMs. This high concentration raises questions about how much real change TrumpRx.gov can bring.
Cuban remains hopeful, stating, “If they force PBMs to change, Trump gets all the credit.” Whether this online pharmacy delivers on its promise may hinge on its ability to disrupt the established system that many believe is rigged in favor of big middlemen.
In discussions about drug pricing reform, it’s important to consider what different stakeholders think. Some experts believe that a shift toward more transparent pricing and direct consumer access can decrease overall drug costs. However, until the launch, many remain cautiously optimistic about whether the initiative will live up to its potential.
For more insights into the interplay between drug pricing and health care policies, you can read more on the NPR Health section.
Source link
drug,pbm,rebate,manufacturer,trump,company,cuban,trumprx,gov,cost,patient,business insider,mark cuban weighs,stock price,drugs
